Enríquez de Salamanca Gambara Rodrigo, Sierra Santos Ana María, Ruiz San Pedro Ana María, Montero Cuadrado Federico, Muñoz León Irene, Castro Villamor Miguel Ángel, Córdoba Romero Alicia, Del Olmo Tornero Ana María, Pérez Pérez Lucía, Morales-Quezada León
Primary Care Management of Valladolid Oeste, 47012 Valladolid, Spain.
Primary Care Management of Valladolid Este, 47005 Valladolid, Spain.
Life (Basel). 2025 Jan 16;15(1):114. doi: 10.3390/life15010114.
Chronic non-cancer pain (CNCP) is one of the leading causes of disability. The use of strong opioids (SOs) in the management of CNCP is increasing, although evidence supporting their use remains limited. Primary care (PC) plays a key role in this context. Our objectives were to determine the prevalence and profile of patients using SOs for CNCP in PC consultations in Valladolid in 2022, and to describe the consumption of SO prescribed for CNCP from 2020 to 2023. We conducted a descriptive and retrospective study using data extracted from the Pharmaceutical Consumption Information System of Castilla y León. Patients in Valladolid with SO use for more than three months due to CNCP were analyzed. Sociodemographic and clinical characteristics of these patients in 2022 were described. The number of defined daily doses (nº DDDs) and costs from 2020 to 2023 were analyzed. A total of 3642 patients were included (0.7% of the population of Valladolid), 71.8% of whom were women. Of the patients, 62.4% were aged 70 or older, 39.8% lived in rural areas, and 9.9% resided in nursing homes. The most frequently prescribed SOs in nº DDDs were fentanyl and tapentadol. The highest consumption in nº DDDs was in patients who lived in nursing homes, were over 70 years old and were resident in rural areas. The number of DDDs from 2020 to 2023 for SOs in DCNO increased by 41%. In total, 0.7% of the population of Valladolid consumes SOs for CNCP, mostly women and people over 70 years old. The consumption of strong opioids in DDDs grew by 41% from 2020 to 2023.
慢性非癌性疼痛（CNCP）是导致残疾的主要原因之一。尽管支持使用强阿片类药物（SOs）治疗CNCP的证据仍然有限，但在CNCP管理中使用强阿片类药物的情况正在增加。在这种情况下，初级保健（PC）起着关键作用。我们的目标是确定2022年巴利亚多利德初级保健咨询中使用SOs治疗CNCP的患者的患病率和概况，并描述2020年至2023年为CNCP开具的SOs的消耗量。我们使用从卡斯蒂利亚-莱昂药品消费信息系统中提取的数据进行了一项描述性回顾性研究。分析了巴利亚多利德因CNCP使用SOs超过三个月的患者。描述了这些患者在2022年的社会人口统计学和临床特征。分析了2020年至2023年的限定日剂量数（nº DDDs）和费用。总共纳入了3642名患者（占巴利亚多利德人口的0.7%），其中71.8%为女性。在这些患者中，62.4%的年龄在70岁及以上，39.8%生活在农村地区，9.9%居住在养老院。按nº DDDs计算，最常开具的SOs是芬太尼和曲马多。按nº DDDs计算，消耗量最高的是居住在养老院、70岁以上且居住在农村地区的患者。2020年至2023年，用于CNCP的SOs的DDDs数量增加了41%。总的来说，巴利亚多利德0.7%的人口因CNCP使用SOs，主要是女性和70岁以上的人。从2020年到2023年，强阿片类药物的DDDs消耗量增长了41%。
